Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
GLP-1 weight loss medications (Wegovy, Zepbound, Foundayo) prescribed by a real clinician, paired with personalized nutrition and ongoing monitoring
Pathophysiology of diabetic kidney disease and therapeutic targets of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists
In the previous two years, Blue Cross reported record operating losses of about $380 million and $400 million, while in 2025, Point32 marked its fifth year of multimillion dollar operating losses
Pain, soreness and recovery are subjective and highly variable outcomes
US$ 23.09
US$ 20.20
US$ 22.21
US$ 24.63
US$ 29.15
